Private View: Discussing Women's Health

Share this article:
Private View: Discussing Women's Health
Dan Chichester

Hot flashes, weight gain, intimacy issues: these are old friends. Am I oversharing? The fact is that menopause and women's health was my entrée into healthcare. Helping evolve the Knowmenopause website also evolved my POV, as an ad professional—and as a human being. Learning medical details was “easy.” What confounded me was the tone-deaf surround-sound confronting too many women, from society… and even some health pros: “It's the same for everyone, honey, so deal!” Suddenly, I wasn't crafting clever promotions for B2B tech or 3-in-1 cable service. Now I had a responsibility to, and increasing respect for, individuals who were confronting this change—indeed, “The Change”—in their bodies and lives.

Even as I've engaged with other serious conditions, those first lessons stay with me. An opportunity to revisit the field, even through others' eyes, is a chance to reflect, anew, on what should drive all our contributions to an active health dialogue.

Here's to responsibility and respect…

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?